

ISPOR 2024 Poster Presentation References

Title:

Buprenorphine Adherence Trajectories, Persistence, and Healthcare Expenditures Among Commercially Insured Patients with Opioid Use Disorder

Authors:

Olateju OA, BPharm, MSc and Thornton JD, PharmD, PhD.

References:

1. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. *Harv Rev Psychiatry* [Internet]. 2015 Mar 18 [cited 2024 Mar 27];23(2):63–75. Available from: <https://pubmed.ncbi.nlm.nih.gov/25747920/>
2. Ronquest NA, Willson TM, Montejano LB, Nadipelli VR, Wollschlaeger BA. Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder. *Subst Abuse Rehabil* [Internet]. 2018 Sep 21 [cited 2023 Oct 30];9:59–78. Available from: <https://www.dovepress.com/relationship-between-buprenorphine-adherence-and-relapse-health-care-u-peer-reviewed-fulltext-article-SAR>
3. Lo-Ciganic WH, Donohue JM, Kim JY, Krans EE, Jones BL, Kelley D, et al. Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States. *Pharmacoepidemiol Drug Saf* [Internet]. 2019 Jan 1 [cited 2023 Dec 10];28(1):80–9. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/pds.4647>
4. Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O'Grady KE, et al. Retention in methadone and buprenorphine treatment among African Americans. *J Subst Abuse Treat* [Internet]. 2013 Sep 1 [cited 2024 Mar 27];45(3):287–92. Available from: <http://www.jsatjournal.com/article/S0740547213000603/fulltext>
5. Nagin DS, Jones BL, Passos VL, Tremblay RE. Group-based multi-trajectory modeling. *Stat Methods Med Res* [Internet]. 2018 Jul 1 [cited 2023 Dec 11];27(7):2015–23. Available from: <https://journals.sagepub.com/doi/10.1177/0962280216673085>